Millions of older Americans with mild-to-moderate hearing loss now face a stark choice between over-the-counter hearing aids priced at $200 to $600 a pair and prescription devices that can run $4,000 to $6,000. Original Medicare covers neither option, leaving enrollees to absorb the full cost out of pocket regardless of which route they take. That coverage gap, combined with a regulatory shift that created an entirely new device category in 2022, is reshaping how people access hearing care and raising questions about who benefits most from the change.
Why the OTC price gap hits hardest right now
The FDA established the over-the-counter hearing aid category for adults with mild-to-moderate loss, allowing buyers to skip the prescription, medical exam, and audiologist fitting that traditional devices require. That single regulatory decision opened retail shelves and online storefronts to a product class that had been gated behind clinical gatekeepers for decades.
The tension is straightforward. Prescription hearing aids still carry price tags that put them out of reach for many fixed-income households, while OTC devices offer a fraction of the cost but come without professional calibration. CMS confirms that Original Medicare does not cover hearing aids or, in most cases, the exams needed to fit them. Medicare does pay for certain diagnostic audiology services, but the benefit boundary stops well short of the device itself. That leaves tens of millions of Medicare enrollees with no federal subsidy for either the cheaper or the more expensive option.
One hypothesis worth tracking is whether seniors in states that did not expand Medicaid shift to OTC devices faster than those in expansion states. In non-expansion states, lower-income adults who age into Medicare may have had less prior access to hearing care through Medicaid, making the no-prescription OTC path more attractive. Testing that idea requires comparing CMS claims data for audiology diagnostic codes before and after the 2022 rule, broken out by state expansion status. No public dataset has yet produced that comparison, which means the question remains open but answerable with existing federal records.
What federal records show about coverage and oversight
Three federal agencies anchor the evidence trail. The FDA’s consumer guidance spells out that OTC hearing aids can be purchased in stores or online without a prescription or medical exam, but the agency also draws a clear line between these devices and personal sound amplification products, which are not regulated as hearing aids. The GAO cataloged the new device category’s rollout in a recent report, providing one of the most detailed federal accounts of how the OTC market took shape after the rule’s finalization.
On the coverage side, CMS documentation distinguishes between audiology services that Medicare will reimburse and hearing aid purchases that it will not. The Medicare Benefit Policy Manual and related Code of Federal Regulations citations set the legal boundary. Diagnostic hearing tests ordered by a physician to evaluate a medical condition are covered. Hearing tests conducted solely to fit a device are not. That distinction matters because it means a Medicare enrollee can get a diagnosis at little or no extra cost but must then pay entirely out of pocket for the device that addresses it.
Payment rules are further laid out in CMS materials on audiology services, which specify how Medicare reimburses clinicians for diagnostic work. Those schedules clarify that while the program will pay for tests to assess hearing and related conditions, it still draws a bright line against funding the hardware that restores hearing function.
Gaps in adoption data and what researchers need next
Despite the regulatory clarity, there is still no comprehensive national picture of how quickly older adults are adopting OTC hearing aids. Retailers and manufacturers report brisk sales, but those figures are proprietary and often bundled with other audio products. Because OTC devices do not require a prescription, they also generate fewer claims records, limiting what can be inferred from Medicare billing alone.
Researchers looking to track uptake face several constraints. First, Medicare claims can show trends in diagnostic audiology visits before and after 2022, but they cannot directly reveal whether a patient chose an OTC or prescription device afterward. Second, state-level variation in Medicaid eligibility and supplemental benefits complicates any attempt to isolate the effect of the federal OTC rule from other coverage changes. Third, many older adults rely on family members, credit cards, or retail financing to pay for devices, none of which leave a standardized data trail.
Still, there are promising avenues. Linking Medicare claims for diagnostic hearing tests with survey data that ask about device type, price paid, and purchase location could begin to fill the gap. Comparing patterns across Medicaid expansion and non-expansion states, as well as between urban and rural counties, would help test whether OTC access is narrowing or widening existing disparities. Additional GAO or HHS evaluations could also clarify whether current consumer protections and labeling requirements are sufficient for an increasingly complex retail marketplace.
For now, the policy landscape leaves older adults navigating a fragmented system: federal regulators have opened the door to cheaper devices, but federal insurance has not followed them through it. Until coverage rules catch up-or until more robust data show that OTC products can reliably substitute for professionally fitted aids-the central trade-off for Medicare enrollees will remain the same: pay less and forgo clinical support, or pay far more for a device that comes with expert guidance but no help from Medicare in covering the bill.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
